Wall Street brokerages expect that Waters Co. (NYSE:WAT) will post sales of $602.25 million for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Waters’ earnings, with the highest sales estimate coming in at $607.80 million and the lowest estimate coming in at $596.12 million. Waters posted sales of $596.22 million during the same quarter last year, which would suggest a positive year over year growth rate of 1%. The business is scheduled to report its next quarterly earnings results on Tuesday, July 23rd.

According to Zacks, analysts expect that Waters will report full year sales of $2.46 billion for the current year, with estimates ranging from $2.44 billion to $2.48 billion. For the next financial year, analysts expect that the business will report sales of $2.58 billion, with estimates ranging from $2.54 billion to $2.63 billion. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Waters.

Waters (NYSE:WAT) last announced its quarterly earnings results on Tuesday, April 23rd. The medical instruments supplier reported $1.60 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.73 by ($0.13). The company had revenue of $513.90 million during the quarter, compared to analysts’ expectations of $545.82 million. Waters had a net margin of 24.59% and a return on equity of 39.64%. The business’s revenue for the quarter was down 3.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.59 earnings per share.

WAT has been the topic of a number of research reports. Zacks Investment Research lowered shares of Waters from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 12th. ValuEngine lowered shares of Waters from a “buy” rating to a “hold” rating in a research report on Wednesday, April 24th. UBS Group lowered their target price on shares of Waters from $248.00 to $230.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 24th. Cleveland Research lowered shares of Waters from a “neutral” rating to an “underperform” rating in a research report on Wednesday. Finally, Barclays lowered their target price on shares of Waters from $218.00 to $210.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 24th. Four investment analysts have rated the stock with a sell rating, ten have given a hold rating and one has given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $208.71.

Waters stock traded down $3.53 during mid-day trading on Friday, hitting $204.36. The company had a trading volume of 870,149 shares, compared to its average volume of 623,612. The firm has a market capitalization of $14.50 billion, a P/E ratio of 24.61, a P/E/G ratio of 2.20 and a beta of 1.08. Waters has a 1 year low of $167.93 and a 1 year high of $255.21. The company has a quick ratio of 2.89, a current ratio of 3.44 and a debt-to-equity ratio of 1.15.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Fundsmith LLP lifted its holdings in Waters by 0.9% in the first quarter. Fundsmith LLP now owns 5,026,757 shares of the medical instruments supplier’s stock valued at $1,265,285,000 after acquiring an additional 43,498 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in Waters by 5.8% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,863,115 shares of the medical instruments supplier’s stock valued at $917,426,000 after acquiring an additional 267,576 shares during the period. Geode Capital Management LLC lifted its holdings in Waters by 10.4% in the first quarter. Geode Capital Management LLC now owns 1,132,012 shares of the medical instruments supplier’s stock valued at $284,491,000 after acquiring an additional 106,671 shares during the period. Northern Trust Corp lifted its holdings in Waters by 5.9% in the first quarter. Northern Trust Corp now owns 991,892 shares of the medical instruments supplier’s stock valued at $249,670,000 after acquiring an additional 54,938 shares during the period. Finally, Champlain Investment Partners LLC lifted its holdings in Waters by 1.5% in the first quarter. Champlain Investment Partners LLC now owns 838,625 shares of the medical instruments supplier’s stock valued at $211,090,000 after acquiring an additional 12,365 shares during the period. 92.63% of the stock is owned by hedge funds and other institutional investors.

Waters Company Profile

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

Further Reading: Do equity income investments outperform growth and income investments?

Get a free copy of the Zacks research report on Waters (WAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Waters (NYSE:WAT)

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.